Brian G. Weinshenker, MD

The professor of neurology at the University of Virginia discussed the progress made in recognizing and diagnosing neuromyelitis optica spectrum disorder through the discovery of specific monoclonal antibodies. [WATCH TIME: 5 minutes]

Experts in neurology discuss immune tolerance as an alternative strategy and share practice pearls for approaching treatment of NMOSD.

Drs Brian Weinshenker, Flavia Nelson, Robert Shin, and Aaron Miller review the unmet needs in the treatment of NMOSD as well as hopes for the future.

Experts in neurology comment on disability and hospitalization rates of NMOSD, as well as how they approach treatment of NMOSD in clinical practice.

Neurology experts expand on advantages and disadvantages of using FDA-approved treatment compared with other therapy options for neuromyelitis optica spectrum disorder.

Robert Shin, MD, FAAN, discusses the potential advantages of using inebilizumab over rituximab in the treatment of NMOSD.

With a plethora of new treatments for NMOSD, a panel discusses safety concerns.

Experts in neurology discuss newly approved medications in the treatment of neuromyelitis optica spectrum disorder, including inebilizumab, eculizumab, and satralizumab.

Drs Brian Weinshenker, Flavia Nelson, Robert Shin, and Aaron Miller discuss the current neuromyelitis optica spectrum disorder treatment landscape.

Expert neurologists review treatment goals in patients with neuromyelitis optica spectrum disorder and share insights on long-term disease-modifying therapies.

Experts in neurology discuss the progression of neuromyelitis optica spectrum disorder, focusing on acute relapse and pseudo attacks.

Aaron Miller, MD, FAAN, reviews the pathophysiology of neuromyelitis optica spectrum disorder and the role of aquaporin-4 in the disease pathway.

Flavia Nelson, MD, and Robert Shin, MD, FAAN, provide insight on the forms of neuromyelitis optica spectrum disorder and how its attacks differ from multiple sclerosis.

Aaron Miller, MD, FAAN, provides an overview of neuromyelitis optica spectrum disorder (NMOSD).

Mayo Clinic’s Brian G. Weinshenker, MD, compares multiple sclerosis with neuromyelitis optica spectrum disorders (NMOSD) and explains why community neurologists need to receive more education on NMOSD risk factors and symptoms.

The professor of neurology at the Mayo Clinic College of Medicine highlighted the importance of the diagnostic process and implementing an early treatment regimen for patients with NMOSD.

The professor of neurology at Mayo Clinic College of Medicine discussed which biomarkers have shown the most relevancy in NMOSD and which deserve more attention.

The professor of neurology at Mayo Clinic College of Medicine discussed several areas within the neuromyelitis optica spectrum disorder that are of interest for ongoing and new research efforts.

The professor of neurology at Mayo Clinic College of Medicine discussed the 3 currently FDA-approved agents for NMOSD and other agents currently within the clinical pipeline.

The professor of neurology at Mayo Clinic College of Medicine discussed lesser-known facets of NMOSD and how the disease evolves over time.

The professor of neurology at the Mayo Clinic College of Medicine detailed the strides made in recognizing NMOSD as its own disease, along with specific biomarkers that identify it.

The professor of neurology at the Mayo Clinic College of Medicine discussed the need for evaluating infection risk of disease-modifying therapies amid a growing MS treatment landscape.